Forte Biosciences
Manufacturing · Texas, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
3060 Pegasus Park Dr Bldg 6, Dallas, Tex...Phone Number
(310) 618-6994Website
www.fortebiorx.comRevenue
<$5 MillionStock Symbol
FBRXIndustry
ZI Rank: 1
Signal Type
Jan
Feb
Mar
Apr
May
Jun
ZI Rank
2
1
1
1
1
1
About Forte Biosciences
Forte Biosciences is a biopharmaceutical company focused on autoimmune diseases. Fortes lead product, FB-102, is a proprietary molecule for the treatment of autoimmune and autoimmune related diseases. The company's initial focus will be on Graft-versus-Host Disease (GvHD), Vitiligo and Alopecia Areata, large indications with unmet needs. GvHD is a common potentially life-threatening complication commonly associated with allogeneic hematopoietic stem cell transplantation. Vitiligo is a chronic disorder that causes patches of skin to lose pigment or color. Alopecia Areata is where patches of hair loss occur on the scalp or the body.Explore more
Forte Biosciences Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is Forte Biosciences your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
Check out if Forte Biosciences is spiking on competitors!
Check if Forte Biosciences has recently received funding, and reach out quickly before it becomes old news!
Earning: See what the market has to say on Forte Biosciences recently announced quarterly report
Click to see if Forte Biosciences had a recent Job posting/layoffs
Website visits: Recent activity has been detected on your website
Congratulate Masked Content for being promoted to Masked Content at Forte Biosciences
Product Launch: Get notified when Forte Biosciences launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Forte Biosciences, which may be a good buyer, showed buying intent in Masked Content Topic
Funding: Get notified immidiatlly once Forte Biosciences has new funding data
Recommended Actions
Find VP level buyers at Forte Biosciences
Find more new buyers
Compare Similar Companies to Forte Biosciences
Compare insights from companies similar to Forte Biosciences, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
Forte Biosciences is experiencing very low activity levels compared to other companies in the Manufacturing sector.
What does this means?
Forte Biosciences is drawing exceptional interest within the Manufacturing industry, suggesting notable developments or strong market momentum, learn more about Forte Biosciences.
Forte Biosciences financials insights
Gather financial insights about Forte Biosciences, including details on funding rounds, investors, total funding, and acquisitions, to gain a comprehensive understanding of their financial strategy.
2023
Other Financing Round
$25M
2024
Private Equity
$53M
Forte Biosciences Tech Stack
A closer look at the technologies used by Forte Biosciences
See more technologies
Most Recent Scoops
Project
Laboratory Operations, Medical Research, Clinical Operations
Funding
Funding
Earnings
Clinical Operations, Operations, Regulations
Earnings
Earnings
Clinical Operations, Operations
Forte Biosciences News & Media
Forte Biosciences shares surge after argenx agrees to acquire company for $2.2B
Forte Biosciences (NASDAQ:FBRX) shares surged about 40% to around $76 on Monday after argenx (NASDAQ:ARGX) announced an agreement to acquire the biotechnology company in a deal valued at approximately $2.2 billion. Under the terms of the agreement, argenx will acquire all outstanding Forte...Forte Biosciences shares jump after $2.2 billion takeover agreement with argenx
Forte Biosciences (NASDAQ:FBRX) shares climbed 39. 2% in pre-market trading after argenx (NASDAQ:ARGX) announced a definitive agreement to acquire the clinical-stage biotechnology company in an all-cash transaction valued at approximately $2.Forte Biosciences reports positive results from Phase Ib trial for vitiligo
Across all study participants, 34.4% of those treated with FB102 reached FVASI50 and 12.5% attained FVASI75 at week 24.
Read more news
Top Manufacturing Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding Forte Biosciences
Sign Up For FreeTo access detailed company insights
Forte Biosciences is a biopharmaceutical company focused on autoimmune diseases. Fortes lead product, FB-102, is a proprietary molecule for the treatment of autoimmune and autoimmune related diseases. The company's initial focus will be on Graft-versus-Host Disease (GvHD), Vitiligo and Alopecia Areata, large indications with unmet needs. GvHD is a... Read More
